Shopping cart
. Ed(S): Tabrizi, Mohammad Ali Karimzadeh; Bornstein, Gadi Gazit; Klakamp, Scott L. - Development of Antibody-Based Therapeutics - 9781489991133 - V9781489991133
Stock image for illustration purposes only - book cover, edition or condition may vary.

Development of Antibody-Based Therapeutics

€ 219.59
FREE Delivery in Ireland
Description for Development of Antibody-Based Therapeutics Paperback. This book examines vital considerations in designing effective translational strategies in the development of antibody-based therapeutics, including the relationship between the 'unit dose' and 'unit effect' with respect to beneficial and deleterious effects. Editor(s): Tabrizi, Mohammad Ali Karimzadeh; Bornstein, Gadi Gazit; Klakamp, Scott L. Num Pages: 426 pages, 14 black & white tables, biography. BIC Classification: MMG; MQP; PSB. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 23. Weight in Grams: 670.
Translational strategies for development of antibody-based therapeutics should allow understanding of the relationship between the ‘unit dose’ and ‘unit effect’ with respect to both beneficial and deleterious effects from early stages of development. The flow of information from later to earlier stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Selection and evaluation of relevant biomarkers in early preclinical development in "relevant" animal models should allow for identifying potential risks to humans and establishing safe First-In-Human (FIH) dosing strategies. Hence, integration of knowledge with respect to target antigen properties such as antigen ... Read more

Product Details

Publication date
Springer-Verlag New York Inc. United States
Number of pages
Number of Pages
Place of Publication
New York, United States
Shipping Time
Usually ships in 15 to 20 working days

About . Ed(S): Tabrizi, Mohammad Ali Karimzadeh; Bornstein, Gadi Gazit; Klakamp, Scott L.
Mohammad Tabrizi, Ph.D., Vice President, Preclinical Development, AnaptysBio Inc. Mohammad Tabrizi is a leader in translational sciences as related to development of antibody-based therapeutics. His product development experience spans many therapeutic areas including oncology and inflammatory disease, and his technical expertise includes preclinical pharmacology and safety, preclinical and clinical pharmacokinetics, pharmacodynamics, GLP-compliant bioanalytics, and clinical pharmacology of therapeutic monoclonal antibodies. ... Read more

Reviews for Development of Antibody-Based Therapeutics

Goodreads reviews for Development of Antibody-Based Therapeutics

Subscribe to our newsletter

News on special offers, signed editions & more!